Monopar Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
/ 
Frequently asked questions
To buy Monopar Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Monopar Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Monopar Therapeutics Inc. is MNPR:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Monopar Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Monopar Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Monopar Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Monopar Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Monopar Therapeutics Inc..